ProDGNE is a 3 year transnational pre-clinical research project which aims to develop an innovative therapeutic compound to treat GNE Myopathy (GNEM), an ultra rare muscle disease affecting young adults. ProDGNE represents a unique joint collaboration among patients, European and Canadian experts in clinical GNE Myopathy, sialic acid, organic synthesis, and -OMIC technologies.